Error message

Deprecated function: Using ${var} in strings is deprecated, use {$var} instead in include_once() (line 1442 of includes/bootstrap.inc).
Deprecated function: Using ${var} in strings is deprecated, use {$var} instead in include_once() (line 1442 of includes/bootstrap.inc).
Deprecated function: Optional parameter $type declared before required parameter $nid is implicitly treated as a required parameter in include_once() (line 1442 of includes/bootstrap.inc).

A.83 EPC Disclosure of the invention

The European patent application shall disclose the invention in a manner sufficiently clear and complete for it to be carried out by a person skilled in the art.

[ Art. 78 80 100 138 R. 31 34 40 42 ]

See decision/opinion of the Enlarged Board of Appeal G 2/93, G 2/98 (Annex I).

Source: http://www.epo.org/law-practice/legal-texts/html/epc/2016/e/ar83.html

Date retrieved: 17 May 2021

387 references found. Limiting display to 200 references.

Click X to load a reference inside the current page, click on the title to open in a new page.

EPC Articles

X Chapter I Filing and requirements of the European patent application

X A.78 EPC Requirements of a European patent application

X A.80 EPC Date of filing

X A.100 EPC Grounds for opposition

X A.138 EPC Revocation of European patents

EPC Implementing Rules

X R.31 EPC Deposit of biological material

X R.32 EPC Expert solution

X R.33 EPC Availability of biological material

X R.34 EPC New deposit of biological material

X R.40 EPC Date of filing

X R.42 EPC Content of the description

X R.63 EPC Incomplete search

EPO Guidelines Foreword

X GL FOREWORD 2.1 Overview

EPO Guidelines - A Formalities Examination

X GL A IV 4.1 Biological material; deposit thereof

X GL A IV 4.2 Missing information; notification

EPO Guidelines - B Search

X GL B III 3.6 Broad claims

X GL B IV 1.3 Documents cited or supplied by the applicant

X GL B VIII 3 No meaningful search possible

EPO Guidelines - D Opposition and Limitation/Revocation Procedures

X GL D III 5 Grounds for opposition

EPO Guidelines - E General Procedural Matters

X GL E IV 1.11.1 When may models be submitted?

X GL E VI 3 Observations by third parties

EPO Guidelines - F The European Patent Application

X GL F II 4.1 General remarks

X GL F II 4.3 Background art

X GL F II 4.14 Registered trade marks

X GL F II 6.1 Reference to sequences disclosed in a database

X GL F III 1 Sufficiency of disclosure

X GL F III 2 Art. 83 vs. Art. 123(2)

X GL F III 3 Insufficient disclosure

X GL F III 6.1 Biological material

X GL F III 6.3 Deposit of biological material

X GL F III 7 Proper names, trade marks and trade names

X GL F III 8 Reference documents

X GL F III 9 "Reach-through" claims

X GL F III 10 Sufficiency of disclosure and Rule 56

X GL F III 11 Sufficiency of disclosure and clarity

X GL F III 12 Sufficiency of disclosure and inventive step

X GL F IV 4.5.3 Generalisation of essential features

X GL F IV 4.8 Trade marks

X GL F IV 4.22 Broad claims

X GL F IV 6.4 Lack of support vs. insufficient disclosure

EPO Guidelines - G Patentability

X GL G I 2 Further requirements of an invention

X GL G III 1 General remarks

X GL G VI 6 Implicit disclosure and parameters

X GL G VII 5.2 Formulation of the objective technical problem

EPO Guidelines - H Amendments and Corrections

X GL H II 2.3.1.1 Rule 137(3) in conjunction with Article 83

X GL H V 4.1 The subject-matter to be excluded is not disclosed in the application as originally filed (so-called undisclosed disclaimers)

EPO PCT GL - F (not assigned)

X GL-PCT FOREWORD 3.1 Annex I: EPC-PCT concordance table

EPO Guide for Applicants, part II Int. - C The EPO as ISA and SISA

X GA C5.6.1 5.6.1.

Case Law Book: I Patentability

X CLR I C 3.2.1.H Trade names

X CLR I C 3.2.4.D Internal structure or composition of a product

X CLR I C 3.4.9 Public availability of documents submitted for standardisation

X CLR I C 4.11 Reproducibility of the content of the disclosure

X CLR I D 2 Problem and solution approach

X CLR I D 4.6 Solving a technical problem – post-published documents

X CLR I E 2 Reproducibility and sufficiency of disclosure

Case Law Book: II Conditions to be met by an Application

X CLR II A 1.5 Clarity of claims and Article 83 EPC

X CLR II A 3.1 Introduction and general principles

X CLR II A 3.2 Indication of all essential features

X CLR II A 5.2 Restrictions on generalising the technical information and examples adduced in the description

X CLR II C 1 Introduction

X CLR II C 2 Date of compliance

X CLR II C 3.1 Application as a whole

X CLR II C 3.2 Alleged effect not a feature of the claims

X CLR II C 4.1 The disclosure is aimed at the skilled person

X CLR II C 5.3 Examples

X CLR II C 5.5 Parameters

X CLR II C 6.4 Use to which invention is put

X CLR II C 6.6.4 Forbidden area of the claims

X CLR II C 6.6.7 Experiments

X CLR II C 6.6.8 Measuring methods

X CLR II C 6.6.9 Chemical compounds

X CLR II C 6.7 Trial and error

X CLR II C 7.1.4 Broad claims

X CLR II C 7.2 Level of disclosure required for medical use – plausibility

X CLR II C 7.3 Level of disclosure required for antibodies

X CLR II C 7.4 Factors contributing to a finding of undue burden

X CLR II C 7.6 Deposit of living material

X CLR II C 8.1 ‍‍Article 83 EPC and support from the description

X CLR II C 8.2 ‍‍Article 83 EPC and clarity of claims

X CLR II C 9 Evidence

X CLR II E 1.3.6.C Enabling disclosure

Case Law Book: III Amendments

X CLR III B 2.4.2 Decision must demonstrably show that arguments were heard and considered

X CLR III G 4.3.1 General – "Balance of probabilities"

X CLR III G 5.1.2.C Sufficiency of disclosure

X CLR III G 5.2.2 Cases in which the burden of proof was reversed

Case Law Book: IV Divisional Applications

X CLR IV B 2.6.1 Discretion of the examining division under Rule 137(3) EPC

X CLR IV C 3.4.6 Opportunity to comment on new grounds for opposition

X CLR IV C 5.1.8 Amendments intended to remedy a lack of clarity

Case Law Book: V Priority

X CLR V A 2.6.3.F Objection not raised at first instance

X CLR V A 3.2.1.H Fresh ground for opposition on appeal

X CLR V A 8.2 Department of first instance bound by decision of board of appeal

Case Law of the Enlarged Board

X G 0002/93 (Hepatitis A virus) of 21.12.1994

X G 0002/98 (Requirement for claiming priority of the "same invention") of 31.5.2001

X G 0001/07 (Treatment by surgery/MEDI-PHYSICS) of 15.2.2010

X G 0002/07 (Broccoli/PLANT BIOSCIENCE) of 9.12.2010

X G 0001/08 (Tomatoes/STATE OF ISRAEL) of 9.12.2010

X G 0002/10 (Disclaimer/SCRIPPS) of 30.8.2011

X G 0003/14 () of 24.3.2015

General Case Law

X R 0015/09 (Schwerwiegender VerstoÃ gegen Art. 113 EPÃ/GLAS PLATZ) of 5.7.2010

X R 0007/12 () of 6.12.2013

X R 0016/12 () of 15.11.2013

X R 0005/16 (Petition clearly unallowable) of 24.10.2016

X T 0601/05 (Anti-TNF alpha human monoclonal antibodies/BAYER III) of 2.12.2009

X T 1421/05 () of 18.1.2011

X T 0578/06 (Pancreatic cells/IPSEN) of 29.6.2011

X T 0699/06 (Morphogenesis/STRYKER) of 29.6.2010

X T 0911/06 (Order of the requests/DA PONTE) of 11.11.2009

X T 1063/06 (Reach-through claim/BAYER SCHERING PHARMA AKTIENGESELLSCHAFT) of 3.2.2009

X T 1456/06 (Telomerase/GERON) of 31.3.2011

X T 1625/06 (Adaptive air interface waveform/POWERWAVE) of 17.6.2010

X T 1886/06 (PigmentprÃ¤paration/MERCK) of 23.10.2009

X T 0146/07 (Prenatal diagnosis/ISIS) of 13.12.2011

X T 0230/07 (Colloidal binder/PAROC) of 5.5.2010

X T 0305/07 (Trisulfides/PFIZER) of 20.5.2011

X T 0418/07 (Human anti-TNFalpha antibodies/ABBOTT) of 4.5.2011

X T 0433/07 (Opsonic antibodies/HENRY M. JACKSON FOUNDATION) of 11.1.2011

X T 0617/07 (Monoclonal NGF-antagonist antibodies/LAY LINE) of 4.8.2009

X T 0870/07 (Epoxy enantiomer/NISSAN) of 6.10.2009

X T 0990/07 () of 23.2.2010

X T 1014/07 (Saturated dicarboxylic acids/COGNIS) of 2.7.2012

X T 1205/07 (Adenoviral packaging system/CRUCELL) of 20.9.2011

X T 1329/07 () of 11.11.2010

X T 1437/07 (Botulinum toxin for treating smooth muscle spasm/ALLERGAN) of 26.10.2009

X T 1614/07 () of 20.11.2009

X T 1659/07 (TFO-Betrieb/IPCOM) of 21.1.2010

X T 1728/07 (Florfenicol synthesis/SCHERING) of 11.10.2010

X T 1731/07 () of 18.12.2012

X T 1854/07 (Oil from seeds/CONSEJO SUPERIOR) of 12.5.2010

X T 1993/07 (Continuous polymerisation/CHEVRON) of 13.10.2011

X T 2023/07 (Flavonoids for cystic fibrosis therapy/CHILDREN'S HOSPITAL & … of 22.12.2010

X T 0070/08 () of 9.9.2010

X T 0079/08 () of 28.10.2010

X T 0109/08 (Dental Composite/KERR) of 27.1.2012

X T 0120/08 () of 14.10.2010

X T 0155/08 (IMPDH-Inhibitoren/BAYER CROPSCIENCE) of 14.6.2012

X T 0369/08 () of 28.4.2010

X T 0386/08 (Humanized antibodies to the amyloid beta peptide/WASHINGTON … of 22.11.2010

X T 0390/08 (Without hydrocarbon/TOPSOE) of 29.6.2011

X T 0413/08 () of 8.12.2009

X T 0491/08 (Improved immunogenicity/GOVERNMENT USA) of 21.10.2010

X T 0623/08 (RNA virus/DNAVEC) of 18.9.2009

X T 0716/08 (Infectious salmon anaemia virus vaccine/INTERVET) of 19.8.2010

X T 0778/08 () of 7.12.2010

X T 0824/08 (Non-segmented negative strand RNA viruses/CRUCELL) of 20.11.2012

X T 0830/08 (Rimcazole/DUNDEE) of 11.10.2010

X T 0959/08 () of 10.11.2009

X T 1069/08 (Desaturase/CALGENE) of 8.9.2011

X T 1133/08 () of 12.7.2011

X T 1250/08 () of 16.3.2011

X T 1364/08 (Cellular proliferative disorders/ONCOLYTICS) of 10.11.2010

X T 1407/08 () of 20.3.2013

X T 1547/08 () of 4.4.2011

X T 1610/08 () of 21.9.2011

X T 1841/08 () of 9.10.2012

X T 1900/08 () of 19.4.2012

X T 1926/08 () of 3.5.2011

X T 2003/08 (Dilated cardiomyopathy/EDWARDS) of 31.10.2012

X T 2006/08 (Conjugated factor IX/BIOVITRUM) of 18.10.2011

X T 2181/08 (TREM-1 splice variant/GENEPRINT) of 14.11.2012

X T 2285/08 () of 15.4.2011

X T 2351/08 (Hsp70 Protein/ Multhoff) of 8.9.2009

X T 0015/09 () of 19.12.2012

X T 0018/09 (Neutrokine/HUMAN GENOME SCIENCES) of 21.10.2009

X T 0022/09 (Fischer-Tropsch Catalysts/ Sasol) of 5.2.2016

X T 0045/09 (Silice prÃ©cipitÃ©e/RHODIA) of 19.1.2011

X T 0075/09 () of 13.9.2011

X T 0108/09 (Fulvestrant for treating resistant breast cancer/ASTRA ZENECA AB) of 14.2.2013

X T 0189/09 () of 27.7.2011

X T 0228/09 () of 28.9.2012

X T 0482/09 (WaschmittelformkÃ¶rper/HENKEL) of 14.7.2011

X T 0494/09 (Solution de facteur VIII sÃ©curisÃ©e viralement/LABORATOIRE FRANÃAIS) of 28.9.2011

X T 0611/09 (Catheter lock solution/ASH ACCESS TECHNOLOGY, INC.) of 18.10.2011

X T 0756/09 (Fluid flow simulation/MOLDFLOW) of 18.3.2015

X T 0775/09 (ErhÃ¶hung Glykosilierung/ROCHE) of 20.3.2012

X T 0808/09 () of 28.2.2013

X T 0852/09 (Enhancers/AVENTIS PHARMACEUTICALS INC. et al.) of 6.9.2013

X T 0967/09 (Influenza vaccines/ABBOTT BIOLOGICALS) of 4.11.2014

X T 1051/09 () of 7.2.2012

X T 1273/09 (Homeopathic mixture/EPSHTEIN) of 20.2.2013

X T 1439/09 (Sclerostin/UCB PHARMA) of 16.4.2013

X T 1457/09 (CTL epitopes of WT-1/GANYMED PHARMACEUTICALS) of 17.1.2014

X T 1616/09 (Combination therapy with anti-neoplastic agent and DNA methylation … of 27.8.2014

X T 1627/09 (Desaturases/WASHINGTON) of 10.10.2013

X T 1635/09 (Zusammensetzung fÃ¼r EmpfÃ¤ngnisverhÃ¼tung/BAYER SCHERING PHARMA AG) of 27.10.2010

X T 1712/09 (Silice/RHODIA) of 5.2.2013

X T 1760/09 () of 22.7.2011

X T 2045/09 (Anti-ErbB3 antibody/GENENTECH) of 14.5.2014

X T 0045/10 () of 27.9.2011

X T 0328/10 () of 16.5.2012

X T 0338/10 (Composition anti-allergique/ANTIALIS) of 22.1.2015

X T 0430/10 (Dotierte FÃ¤llungskieselsÃ¤ure/Evonik) of 28.2.2014

X T 0492/10 () of 22.10.2013

X T 0547/10 (Transgenic cotton plants/BAYER CROPSCIENCE) of 13.7.2016

X T 0553/10 (Composite oxide/Nippon Mining) of 11.2.2015

X T 0657/10 (Stearidonic plant delta desaturases/CALGENE) of 19.12.2013

X T 0906/10 (Vaccination per os/NOVARTIS) of 9.4.2013

X T 0915/10 (Soybean event/MONSANTO) of 11.6.2015

X T 0999/10 () of 19.6.2012

X T 1100/10 (Detergent Bacillus lentus subtilisin protease egg stains/BASF) of 18.3.2014

own subtype: guidelines

X GL J G‑II, 3.3.1 Artificial intelligence and machine learning (introduced in GL 2018)